Third Of Drug Makers Extend Drugs In India Rather Than Make New Ones
This article was originally published in PharmAsia News
Executive Summary
Makers of branded drugs are engaged in a trend of extending their drugs rather than launching new ones in India, according to a market study. ORG IMS Health said about a third of brands brought to market each year in India are extensions of existing drugs, and they account for about 18 percent of the value of the domestic market. The study said both multinational companies and local drug makers are engaged in the practice in India. Drugs getting the extensions tend to be those for treating infections, heart problems, dermatology and diabetes, according to the report. (Click here for more
You may also be interested in...
News We’re Watching: AI Safety Partnership; Boston Scientific Recalls; New Cancer, STI Tests; VR
This week, the US and UK announced a partnership to promote AI safety. Boston Scientific recalls embolic agent. LumiCell received FDA approval for its imaging agent to detect residual cancer. Scout receives an award to develop an STI test; and Osso VR leverages the Apple Vision Pro for VR medical training.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.